Am J Transplant, Volume 21, Suppl 3 Archives - Page 38 of 139 - ATC Abstracts

2021 American Transplant Congress
Understanding Delays to Pediatric Kidney Transplant Wait-List Activation: Providers and Families Weigh in
C. M. Farkas-Skiles¹, A. Feinsinger², R. Pines³, A. D. Waterman⁴
¹Pediatric Nephrology, UCLA Mattel Children Hospital, Los Angeles, CA, ²Medicine and Philosophy, UCLA, Los Angeles, CA, ³Santa Barbara Cottage Hospital, Santa Barbara, CA, ⁴Nephrology, David Geffen School of Medicine, UCLA, Los Angeles, CA
*Purpose: Since timely access to kidney transplant mediates mortality of children with kidney disease, we examined which factors most commonly affect providers’ decision-making to delay…
2021 American Transplant Congress
Outcomes of Kidney Transplant Recipients with Antibody-mediated Allograft Rejection: A Retrospective Study
A. Al Jurdi¹, L. Goldfarb¹, M. Lafargue², J. Azzi³, L. V. Riella¹
¹Center for Transplantation Sciences, Massachusetts General Hospital, Charlestown, MA, ²Université de Paris, Paris, France, ³Transplantation Research Center, Brigham and Women’s Hospital, Boston, MA
*Purpose: The optimal regimen for treating acute and chronic antibody-mediated rejection (AMR) in kidney transplant recipients has yet to be established. The purpose of the…
2021 American Transplant Congress
Use of Donor-Derived Cell-Free DNA for Assessment of Allograft Rejection After Change in Maintenance Immunosuppression Regimens in the First Year Post Kidney Transplant
M. Walsh, V. Peev, L. Lineberger, M. Brokhof, N. Kenyon, N. Alvey
Rush University Medical Center, Chicago, IL
*Purpose: The purpose of this study was to investigate whether the use of donor-derived cell-free DNA (dd-cfDNA) is an effective screening tool for allograft rejection…
2021 American Transplant Congress
Outcomes of Kidney Transplantation in Patients with Congenital Anomalies of the Kidney and Urinary Tract
O. A. Oto¹, Y. Caliskan², H. Yazici¹, S. Mirioglu³, A. Dirim¹, N. Garayeva¹, S. Safak¹, E. Demir¹, Y. Ozluk⁴, A. Artan¹, A. Turkmen¹, K. Lentine²
¹Nephrology, Istanbul University, Istanbul, Turkey, ²Nephrology, Saint Louis University School of Medicine, Saint Louis, WA, ³Nephrology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey, ⁴Pathology, Istanbul University, Istanbul, Turkey
*Purpose: We aimed to compare the long-term outcomes after kidney transplantation (KTx) in patients with congenital anomalies of the kidney and urinary tract (CAKUT) versus…
2021 American Transplant Congress
First Promising Results of CIAT: A New Kidney Exchange Program for Difficult-to-match Patients
M. de Klerk¹, J. Kal¹, K. Glorie², D. Roelen³, M. Betjes¹, J. Wetering van de¹, M. Kho¹, J. Roodnat¹
¹Erasmus MC, Rotterdam, Netherlands, ²EQI, Erasmus University, Rotterdam, Netherlands, ³LUMC, Leiden, Netherlands
*Purpose: Computerised Integration of Alternative Transplantation (CIAT) programs was developed to increase the chances of highly immunized (HI) and longwaiting (LW) kidney transplant candidates. CIAT…
2021 American Transplant Congress
The Combined Effects of Simultaneous Portal Vein Thrombosis and Renal Dysfunction in Liver Transplant Recipients
M. Molinari¹, C. F. Carillo², D. Dongling¹, D. Jorgensen¹, S. Dharmayan¹, C. Kaltenmeier¹, H. Liu¹, J. Behari¹, V. Rachakonda¹, S. Ganesh¹, C. Hughes¹, A. Tevar¹, H. Al Harakeh¹, B. Emmanuel¹, A. Humar¹, R. Bataller¹
¹University of Pittsburgh Medical Centre, Pittsburgh, PA, ²Medicine, University of Pittsburgh Medical Centre, Pittsburgh, PA
*Purpose: Simultaneous portal vein thrombosis (PVT) and renal dysfunction (RD) have unknown effects after liver transplant (LT). We analyzed the outcomes of patients with simultaneous…
2021 American Transplant Congress
Varicella Hepatitis Mimicking Immune Checkpoint Inhibitor-induced Liver Toxicity
M. J. Weiss¹, X. Zhang², E. K. Spengler¹
¹Gastroenterology and Hepatology, University of Wisconsin, Madison, WI, ²Pathology, University of Wisconsin, Madison, WI
*Purpose: Nivolumab is an anti-PD-1 monoclonal antibody belonging to a class of immune checkpoint inhibitors (ICI) used for many malignancies. A major limitation to their…
2021 American Transplant Congress
Impact of Donation After Circulatory Death Donor Allografts on Outcomes Following Liver Transplantation for Cholangiocarcinoma
S. Kumar¹, S. Lin², J. D. Schold²
¹Digestive Disease Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ²Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH
*Purpose: Improvements in the management of extra-hepatic cholangiocarcinoma (CCA) resulted in allocation of a standardized model for end-stage liver disease (MELD) exception score for liver…
2021 American Transplant Congress
Is Low Systemic Fibrinolytic Activity During the Anhepatic Phase Liver Transplant Surgery Associate with the Dreaded Post-Operative Complication of Hepatic Artery Thrombosis?
H. B. Moore¹, Y. Bababekov¹, J. Pomposelli¹, T. Ferrell¹, F. Azam¹, M. Adams², D. Yoeli¹, R. Choudhury¹, M. Wachs², E. Pomfret¹, T. Nydam¹
¹University of Colorado, Aurora, CO, ²Childrens Hospital Colorado, Aurora, CO
*Purpose: Removal of the native liver during transplantation results in impaired clearance of clot degrading proteins and activation of fibrinolysis as appreciated by Starzl in…
2021 American Transplant Congress
Geographic Divergence in Waitlist Registration and Trends in Waitlist Removal for Liver Transplantation in Patients with Nonalcoholic Steatohepatitis (NASH)
C. Hanlon¹, B. Saberi², L. Yuan¹
¹Internal Medicine - Transplant Hepatology, University of Southern California, Los Angeles, CA, ²Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Boston, MA
*Purpose: This study aims to evaluate regional trends of waitlist (WL) registrations and removal for liver transplantation (LT) among United States (US) adults listed for…